Multiple Sclerosis Clinical Trials in Chicago

Showing 261-280 of 346 trials

A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation

NCT01286753

This open-label, multi-center study will evaluate the safety and efficacy of Vemurafenib (RO5185426) in participants with metastatic or unresectable papillary thyroid cancer (PTC) positive for the BRAF V600 mutation and resistant to radioactive iodine therapy. Participants will receive vemurafenib 960 milligrams (mg) orally twice daily until progressive disease or unacceptable toxicity occurs.

Neoplasms

Hoffmann-La Roche51 participantsStarted Jun 2011

Torrance, California, United States • New Haven, Connecticut, United States • Chicago, Illinois, United States +13 more locations

COMPLETEDPHASE22.2 miles

BIBW 2992 (Afatinib) in Head & Neck Cancer

NCT00514943

The primary objective of this study is to explore the efficacy of BIBW 2992 compared with cetuximab (Erbitux) in patients with metastatic or recurrent head and neck cancer after failure of platinum-containing therapy. In addition, the trial aims to clarify the influence of EGFR genotype on tumor response to the treatment regimens.

Head and Neck NeoplasmsCarcinoma, Squamous Cell

Boehringer Ingelheim124 participantsStarted Aug 2007

Stanford, California, United States • Chicago, Illinois, United States • Chicago, Illinois, United States +33 more locations

A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation

BIBW 2992 (Afatinib) in Head & Neck Cancer

Multiple Sclerosis Trials in Other Cities

Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck

Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)

Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis

Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer

Safety and Tolerability of Glatiramer Acetate

A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

JC-Virus (JCV) Antibody Program

Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.

Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib

Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients

Safety and Efficacy Study of AR08 for the Treatment of Vasomotor Symptoms (VMS)

Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis

Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen

A Multiple Ascending Dose Study of R4733 in Patients With Advanced Solid Tumors.

A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors

BAY1238097, First in Man

A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer

Other Conditions in Chicago